DISA's (SGX:532) indirect subsidiary, Digital Life Line, signed a tri-party licensing agreement with the National University Hospital (NUH) and the National University of Singapore (NUS).
Under the deal, the company will aim to commercialize the Mobile Imaging Device for Anterior Segment (MIDAS), a portable cataract screening device co-developed by the NUH and NUS, according to a filing with the Singapore Exchange.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.